Neurocrine Biosciences, Inc. (NBIX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in San Diego, CA, United States. Der aktuelle CEO ist Kyle W. Gano.
NBIX hat IPO-Datum 1996-05-23, 1,800 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $13.13B.
Neurocrine Biosciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medications for neurological, endocrine, and psychiatric disorders. The company's marketed products include INGREZZA for tardive dyskinesia, ONGENTYS for Parkinson's disease, ORILISSA for endometriosis, and ORIAHNN for uterine fibroids, alongside a robust pipeline of clinical-stage candidates targeting epilepsy, major depressive disorder, anhedonia, and schizophrenia. Founded in 1992 and headquartered in San Diego, California, Neurocrine has established strategic partnerships with major pharmaceutical companies including Takeda, AbbVie, Mitsubishi Tanabe Pharma, and others to support its development and commercialization efforts across multiple therapeutic areas.
